Arcus Biosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
3928 POINT EDEN WAY, HAYWARD, CA, 94545
Mailing Address
3928 POINT EDEN WAY, HAYWARD, CA, 94545
Phone
(510) 694-6200
Fiscal Year End
1231
EIN
473898435
Financial Overview
FY2025
$222.00M
Cash & Equivalents
$-3.14
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 10-K Annual financial report | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
Material Events
8-K
Strategy Change
December 12, 2025
High Impact
- Arcus Biosciences discontinued its major late-stage (Phase 3) STAR-221 clinical trial for a cancer drug combination due to futility.
- The drug combination (domvanalimab plus zimberelimab and chemotherapy) failed to improve overall survival in advanced gastric and esophageal cancers compared to existing treatment.
Insider Trading
STRONG SELL
7 insiders
25 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.